VivoSeq
Metabolic & Endocrine

Type 1 Diabetes Mellitus

211

Pipeline Programs↗

28

Active Trials↗

73

Companies Involved↗

Type 1 Diabetes Mellitus is a highly competitive landscape with 211 programs across 73 companies. The most active players are Vertex Pharmaceuticals, Bayhill Therapeutics, Zucara Therapeutics Inc.. 44 therapies are approved with 37 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

43/100

Mech. Concentration

5/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

2 programs

Phase 1B

Bayhill Therapeutics

1 program

Phase 1Z

Zucara Therapeutics Inc.

1 program

Phase 1Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 1G

Gan and Lee Pharmaceuticals, USA

1 program

Phase 1A

AMAG Pharmaceuticals, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical15

Ferumoxytol

Azurity Pharmaceuticals

Formoterol

Viatris

Carbamazepine

Novartis

Mycophenolate Sodium

Novartis

Lantus

Sanofi

Phase 159

ATAZANAVIR

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Glucagon

Xeris Pharmaceuticals

Heparin

Baxter Healthcare Corporation

Siltuximab

RECORDATI GROUP

Rilonacept

Kiniksa Pharmaceuticals (UK), Ltd.

Phase 256

Dulaglutide

Eli Lilly

Hydroxychloroquine

Alnylam Pharmaceuticals

Aldesleukin

Iovance Biotherapeutics, Inc.

Abatacept

Bristol-Myers Squibb

Golimumab

Johnson & Johnson

Phase 337

Basiliximab

Novartis

Candesartan

AstraZeneca

Daclizumab

Roche

Etanercept

Immunex

Ipragliflozin

Astellas

Approved44

Tirzepatide

Eli Lilly

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Verapamil

Val Adams

Ramipril

Viking Therapeutics, Inc.

Lansoprazole

Takeda

Analysis

Modality Breakdown

83%

Small molecule

193 of 233 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody167%Protein / enzyme125%Peptide83%Cell therapy42%

Small molecule leads; the ring shows all 233 classified programs, each share of the total. Modality classified for 99% of 250 pipeline programs.

Analysis

Trial Status

215

clinical trials

Completed155 · 72%
Recruiting14 · 7%
Terminated13 · 6%
Unknown status11 · 5%
Withdrawn8 · 4%
Not yet recruiting7 · 3%
Other7 · 3%

Clinical Trials

Trial Activity

215 trials

Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus
Recruiting·HHangzhou Reprogenix Bioscience, Inc·Phase 1·NCT06731218·10 enrolled
Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus
Recruiting·—·Phase 2·NCT07083882·110 enrolled
Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus
Recruiting·NNanjing Medical University·Phase 3·NCT07258394·90 enrolled
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06280703·118 enrolled
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Recruiting·UUniversity of Chicago·Phase 1/2·NCT06305286·70 enrolled
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Recruiting·MMedtronic MiniMed, Inc.·Preclinical·NCT07228117·400 enrolled
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range of 70 - 180 mg/dl Compared to SMBG
Recruiting·Roche logoRoche·Preclinical·NCT06704672·270 enrolled
A Randomized, Double-blind, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Recently Diagnosed Stage 3 Type 1 Diabetes (T1D)
Recruiting·Sanofi logoSanofi·Phase 3·NCT07088068·723 enrolled
INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes
Recruiting·MMannkind Corporation·Phase 2·NCT07224321·100 enrolled
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 With Recent Onset Stage 3 Type 1 Diabetes
Recruiting·CCOUR Pharmaceutical Development Company, Inc.·Preclinical·NCT06783309·72 enrolled
Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 1 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.
Recruiting·Sanofi logoSanofi·Phase 2·NCT06791291·10 enrolled
Basic Hematological Parameters and Coagulation Profile in Type 1 Diabetic Children
Recruiting·AAssiut University·N/A·NCT06897904·110 enrolled
Type 1 Diabetes Extension Study
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02734277·111 enrolled
Simultaneous Measurement and Responsive Treatment - Part 2
Recruiting·CClinSurge Research·Phase 1·NCT07655076·40 enrolled
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
Active, not recruiting·AAbu Dhabi Stem Cells Center·Phase 1·NCT05413005·10 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)